Media Release Entered into strategic collaboration with Dr. Reddy’s for commercialisation of eftilagimod alfa (efti) in all countries outside North…
REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for…
Wuppertal, Germany, January 29, 2026 - Aicuris Anti-infective Cures AG (“Aicuris”) today announced that the company will be presenting the results…
MELBOURNE, Australia, Jan. 29, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to…
BEIJING, Jan. 29, 2026 (GLOBE NEWSWIRE) -- JAMA Dermatology recently published the results of a Phase II study of novel…
REYKJAVIK, Iceland, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and…
REYKJAVIK, ICELAND (January 29, 2026) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar…
Dr. Mobasher held several executive roles in industry, most recently CMO at BeiGeneIFLI contributed up to $9 million to Enterome’s…
OXFORD, United Kingdom, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies…
Group sales grew by 7%1 at constant exchange rates (CER; 2% in CHF), driven by strong demand for medicines and…